arrow
T

Tycel Phillips

university of michigan
H指数:33
被引数:4,178

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

门诊Brexucabtagene autoleucel在B细胞急性淋巴细胞白血病和套细胞淋巴瘤中的应用

2025-08-200
PREAI
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study

Westin, J.; Phillips, T.J.; Mehta, A.; Hoffmann, M.S.; Gonzalez-Barca, E.; Thieblemont, C.; Bastos-Oreiro, M.; Greil, R.; Giebel, S.; Wei, M.C.; et al. Mosunetuzumab plus Pola-CHP 与 Pola-R-CHP 比较治疗初治 DLBCL 的最终结果:一项 II 期研究。Blood Adv. 2025, 9, 2461–2472. [Google Scholar] [CrossRef]

2025-01-010
OA
Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

急性淋巴细胞白血病(ALL)和套细胞淋巴瘤(MCL)门诊输注Brexucabtagene Autoleucel(brexu-cel)安全且可行

BLOOD
IF23.1
2024-11-050
PRE
Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status

新型疗法(NTs)对复发/难治性(RR)套细胞淋巴瘤(MCL)患者(pts)真实世界(RW)临床结局的影响:按种族/族裔和TP53突变状态分析

BLOOD
IF23.1
2024-11-050
PRE
A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

一项Loncastuximab Tesirine联合Mosunetuzumab治疗复发/难治性弥漫大B细胞淋巴瘤的II期研究

BLOOD
IF23.1
2024-11-050
PRE
Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

真实世界弥漫性大B细胞淋巴瘤(DLBCL)患者的治疗模式与特征:基于美国理赔数据(2017-2024)的回顾性分析

BLOOD
IF23.1
2024-11-050
PRE
Trial in Progress- Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

试验进行中-联盟A052101:一项关于在老年套细胞淋巴瘤患者中,作为一线治疗使用zanubrutinib进行持续与间歇维持治疗的随机III期试验

BLOOD
IF23.1
2024-11-050
PRE
A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

回顾性分析美国商业和医疗保险封闭式理赔数据库,以评估弥漫性大B细胞淋巴瘤患者的真实世界特征和治疗模式(2017-2023)

BLOOD
IF23.1
2024-11-050
PRE
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Epcoritamab治疗复发/难治性大b细胞淋巴瘤: 关键的EPCORE NHL-1试验的2年随访

LEUKEMIA
IF13.4
2024-09-250
OAAI
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study

PI3Kδ 抑制剂zandelisib间歇给药治疗复发/难治性滤泡性淋巴瘤: 一项全球2期研究的结果

2024-08-060
OAAI
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
2023-12-162
OAAI
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Mosunetuzumab联合CHOP治疗未经治疗的DLBCL: 2期研究的安全性和有效性结果

2023-10-1110
OAAI